Yuan Yuan
IP & Legal Senior Director at HuidaGene Therapeutics- Claim this Profile
Click to upgrade to our gold package
for the full feature experience.
-
English Professional working proficiency
-
Chinese Native or bilingual proficiency
Topline Score
Bio
Credentials
-
Exploratory Data Analysis
CourseraSep, 2014- Sep, 2024 -
Getting and Cleaning Data
CourseraAug, 2014- Sep, 2024 -
Professional Qualification Certificate of the Quality Professional
Ministry of Human Resources and Social Security of the PRC; State General Administration of the PRC for Quality Supervision and Inspection and QuarantineJun, 2014- Sep, 2024 -
R Programming
CourseraJun, 2014- Sep, 2024 -
The Data Scientist’s Toolbox
CourseraJun, 2014- Sep, 2024
Experience
-
HuidaGene Therapeutics
-
China
-
Biotechnology Research
-
1 - 100 Employee
-
IP & Legal Senior Director
-
Sep 2021 - Present
Responsibilities: - Developing patent strategy on an international level compatible with the company’s business goal and development - Deeply participating in daily R&D activities and discussing with scientists to identify innovations, determine research directions, design POC experiments, analyze data, generalize or refine inventive concepts - Establishing and managing global patent portfolio, including patent drafting and prosecuting in the US, China, EP, and other carefully selected foreign countries - Daily monitoring of third party’s articles and patents for competitive landscape and FTO - Deeply participating in BD development, especially patent licensing-out negotiation and contracting with Euro and US parties - Establishing and operating in-house system to manage trade secrets, information disclosure, article and poster submission; and registering and managing trademarks - Managing general corporate legal affairs and collaborating with cross-functional teams, including contract drafting and review, labor, compliance, and clinical trials - Supporting introduction and IP & legal due diligence for financing - Managing in-house, external law firm, patent agency, translation agency and controlling budget Show less
-
-
-
King & Wood Mallesons
-
Hong Kong
-
Law Practice
-
700 & Above Employee
-
Senior Patent Attorney
-
Mar 2015 - Sep 2021
Representative Experiences:Hundreds of cases covering patent life cycle management from emergence of innovation to commercial enforcement for domestic and oversea clients including 3M, Air Products, Bayer, Bemis, BMS, Chinese Academy of Sciences, CIT, Dana-Farber, Dow, Illumina, Immunogen, MIT, Merck, Moderna, Monsanto, Novo Nordisk, Novozymes, Roche, Pfizer, Harvard, Sloan-Kettering, Unilever, and especially:- Patent Drafting and Prosecution: + CRISPR-Cas tech, Broad & Harvard & MIT + RNA interference, Alnylam + CAR-T therapy, Novartis + Treatment of Alzheimer’s disease, Chinese Academy of Sciences + Novel stem cells, Tsinghua University- Freedom to Operate (FTO) analysis: + CAR-T products of domestic companies before HK IPO + U-CAR-T products & CRISPR modification of a domestic company before financing + CRISPR gene editing services of an international listed CRO + Antibody (original) of a HK company before financing + Antibody (biosimilars) of a domestic company before financing- Patentability/validity analysis: + Material production patent of an international top enzyme company + Drug patents of an international top pharmaceutical company- Invalidation and Litigation: + Civil infringement litigation and accompanied invalidation for an enzyme product of an international top enzyme company + Administration litigation against Board’s negative decision for an international top pharmaceutical company regarding a glycosylated protein- IP due diligence before financing or IPO: + Review of IP assets, FTO analysis for key commercial products, patentability/validity analysis for key patents, review of IP related agreements Show less
-
-
Patent Intern
-
Nov 2014 - Mar 2015
1. Drafting Observations and amendments to patent application documents; and2. Translating Office Actions from SIPO.
-
-
-
-
Quality Manager
-
Apr 2012 - Sep 2014
Key Achievements: - Establishment of Quality Management System and successful GMP on-site inspection by CFDA - Material preparation and successful registration of China Class III implantable medical device Key Achievements: - Establishment of Quality Management System and successful GMP on-site inspection by CFDA - Material preparation and successful registration of China Class III implantable medical device
-
-
-
Chalmers University of Technology
-
Sweden
-
Research Services
-
700 & Above Employee
-
Research assistant
-
Jan 2011 - Dec 2011
New synthetic reporter system for transcription dynamics analysis in Saccharomyces cerevisiae In order to establish a reporter system of transient promoter activity, 3 variants of TurboGFP and 7 variants of flavin mono-nucleotide binding fluorescent protein(FbFP) with 3 different N-degrons were constructed on plasmid and genome in Saccharomyces cerevisiae. Fluorescent proteins were induced by Gal1 promoter under glucose and galactose conditions. Transcriptional level, translation level and fluorescent intensity were measured to evaluate promoter activity. Show less
-
-
-
China Pharmaceutical University
-
China
-
Pharmaceutical Manufacturing
-
1 - 100 Employee
-
Research assistant
-
Feb 2009 - Jun 2009
Design and Synthesis of central stimulant Modafinil derivatives Modafinil is a new type of central stimulant which direct affect the central nervous system. 12 derivatives of Modafinil analogue were designed and synthesized according to the drug design theory, and all structures were confirmed by IR, MS and H-NMR. Design and Synthesis of central stimulant Modafinil derivatives Modafinil is a new type of central stimulant which direct affect the central nervous system. 12 derivatives of Modafinil analogue were designed and synthesized according to the drug design theory, and all structures were confirmed by IR, MS and H-NMR.
-
-
Education
-
2009 - 2012
Chalmers University of Technology
Master of Science, Chemistry and Bioscience -
2005 - 2009
China Pharmaceutical University
Bachelor of Science, Pharmacy
Community
